牛牛AI助理已提取核心訊息
Avalo Therapeutics, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated December 31, 2023, was submitted by Nantahala Capital Management, LLC, along with individuals Wilmot B. Harkey and Daniel Mack, collectively referred to as the Reporting Persons. According to the document, each of the Reporting Persons may be deemed to beneficially own 42,100 shares of Avalo Therapeutics, which represents 4.9% of the company's outstanding common stock. The filing also notes that the Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock. The shares are held by funds and accounts under the control of...Show More
Avalo Therapeutics, Inc. has been the subject of a recent Schedule 13G/A filing with the United States Securities and Exchange Commission, indicating a change in ownership by certain significant investors. The filing, dated December 31, 2023, was submitted by Nantahala Capital Management, LLC, along with individuals Wilmot B. Harkey and Daniel Mack, collectively referred to as the Reporting Persons. According to the document, each of the Reporting Persons may be deemed to beneficially own 42,100 shares of Avalo Therapeutics, which represents 4.9% of the company's outstanding common stock. The filing also notes that the Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock. The shares are held by funds and accounts under the control of Nantahala Capital Management, with Harkey and Mack having shared voting and dispositive power over these shares. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Nantahala Capital Management identified as an investment adviser and Harkey and Mack as control persons. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Avalo Therapeutics.
Avalo Therapeutics, Inc.是最近向美國證券交易委員會提交的附表13G/A文件的主體，這表明某些重要投資者的所有權發生了變化。該文件日期爲2023年12月31日，由南塔哈拉資本管理有限責任公司以及個人威爾莫特·哈基和丹尼爾·麥克提交，統稱爲申報人。根據該文件，每位申報人均可被視爲實益擁有Avalo Therapeutics的42,100股股票，佔該公司已發行普通股的4.9％。該文件還指出，申報人已不再是超過5％的普通股的受益所有人。這些股票由南塔哈拉資本管理公司控制的基金和賬戶持有，哈基和麥克對這些股票擁有共同的投票權和處置權。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，南塔哈拉資本管理公司被確定爲投資顧問，哈基和麥克被確定爲控制人。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響Avalo Therapeutics的控制權。
Avalo Therapeutics, Inc.是最近向美國證券交易委員會提交的附表13G/A文件的主體，這表明某些重要投資者的所有權發生了變化。該文件日期爲2023年12月31日，由南塔哈拉資本管理有限責任公司以及個人威爾莫特·哈基和丹尼爾·麥克提交，統稱爲申報人。根據該文件，每位申報人均可被視爲實益擁有Avalo Therapeutics的42,100股股票，佔該公司已發行普通股的4.9％。該文件還指出，申報人已不再是超過5％的普通股的受益所有人。這些股票由南塔哈拉資本管理公司控制的基金和賬戶持有，哈基和麥克對這些股票擁有共同的投票權和處置權。該文件是根據1934年《證券交易法》第13d-1（b）條提交的，南塔哈拉資本管理公司被確定爲投資顧問，哈基和麥克被確定爲控制人。該文件稱，這些股份是在正常業務過程中收購的，不是爲了改變或影響Avalo Therapeutics的控制權。
有用
沒用